Literature DB >> 18495276

Assessment of biventricular functional reserve and NT-proBNP levels in patients with RV volume overload after repair of tetralogy of Fallot at young age.

Jochem van den Berg1, Jan L M Strengers, Piotr A Wielopolski, Wim C Hop, Folkert J Meijboom, Yolanda B de Rijke, Frans Boomsma, Ad J J C Bogers, Peter M T Pattynama, Willem A Helbing.   

Abstract

PURPOSE: To assess biventricular functional reserve (FR), NT-proBNP levels and exercise performance, in relation to right ventricular volume in patients with pulmonary regurgitation (PR) after repair of tetralogy of Fallot (TOF) at young age.
METHODS: In 53 TOF patients (maximum age at repair 2.0 years, interval since repair 15 (5) years) without residual lesions except PR, biventricular FR (derived from magnetic resonance imaging with dobutamine stress), NT-proBNP levels, maximal workload, and peak oxygen uptake were assessed.
RESULTS: Mean right ventricular end-diastolic volume was 140(38) ml/m(2). Median pulmonary regurgitant fraction was 37% (range 0-57%). Biventricular systolic stress response was normal: mean (SD) ESV decreased (DeltaRVESV -17(8) ml/m(2), DeltaLVESV -11(5)), SV increased (DeltaRVSV +12(9) ml/m(2), DeltaLVSV +9(6)), FR was positive in all (RV-FR +11(5)%, LV-FR +13(6)). No serious adverse effects to dobutamine were encountered. NT-proBNP was increased in 2 patients. Median level was 10 pmol/L (range 2-42). NT-proBNP correlated with PR-percentage but not with right ventricular size. High-risk levels of NT-proBNP indicated a smaller RV-FR and a smaller decrease of biventricular ESV. Mean (SEM) VO2(max) was 96(3)%, mean Workload(max) 89(2)% of predicted.
CONCLUSION: At mid to long term follow-up overall NT-proBNP levels are normal and biventricular functional reserve and exercise tolerance are well preserved in TOF repaired at young age, irrespective of RV volume. This questions the validity of isolated PR or RV volume criteria for pulmonary valve replacement in this group. Low-dose dobutamine stress testing is well tolerated and may be a useful additional tool for clinical decision making.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18495276     DOI: 10.1016/j.ijcard.2008.01.011

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  NT-proBNP as Marker of Ventricular Dilatation and Pulmonary Regurgitation After Surgical Correction of Tetralogy of Fallot: A MRI Validation Study.

Authors:  Annalisa Paolino; Tarique Hussain; Antonio Pavon; Maria Nieves Velasco; Sergio Uribe; Antonio Ordoñez; Israel Valverde
Journal:  Pediatr Cardiol       Date:  2016-11-21       Impact factor: 1.655

2.  Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

Authors:  Steven E Lipshultz; David C Landy; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M Rovitelli; Cindy Proukou; M Jacob Adams; Tracie L Miller
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

Review 3.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.

Authors:  Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki
Journal:  Eur Heart J       Date:  2016-01-18       Impact factor: 29.983

4.  Right ventricular dysfunction and B-type natriuretic peptide in asymptomatic patients after repair for tetralogy of Fallot.

Authors:  Christian Apitz; Ludger Sieverding; Heiner Latus; Anselm Uebing; Stefan Schoof; Michael Hofbeck
Journal:  Pediatr Cardiol       Date:  2009-05-28       Impact factor: 1.655

Review 5.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 6.  Cardiac biomarkers in children with congenital heart disease.

Authors:  Masaya Sugimoto; Seiko Kuwata; Clara Kurishima; Jeong Hye Kim; Yoich Iwamoto; Hideaki Senzaki
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.